The Journal of Neuroscience, December 1, 2002, 22(23):10302-10312
Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer
of Aromatic L-Amino Acid Decarboxylase, Tyrosine
Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene
Expression, Dopamine Production, and Functional Improvement in a Rat
Model of Parkinson's Disease.
Mimoun
Azzouz*,
Enca
Martin-Rendon*,
Robert D.
Barber,
Kyriacos A.
Mitrophanous,
Emma E.
Carter,
Jonathan B.
Rohll,
Susan M.
Kingsman,
Alan J.
Kingsman, and
Nicholas D.
Mazarakis
Oxford BioMedica (UK) Ltd., Oxford OX4 4GA, United Kingdom
Parkinson's disease (PD) is a neurodegenerative disorder
characterized by the selective loss of dopaminergic neurons in the substantia nigra. This loss leads to complete dopamine depletion in the
striatum and severe motor impairment. It has been demonstrated previously that a lentiviral vector system based on equine infectious anemia virus (EIAV) gives rise to highly efficient and sustained transduction of neurons in the rat brain. Therefore, a dopamine replacement strategy using EIAV has been investigated as a treatment in
the 6-hydroxydopamine (6-OHDA) animal model of PD. A self-inactivating EIAV minimal lentiviral vector that expresses tyrosine hydroxylase (TH), aromatic amino acid dopa decarboxylase (AADC), and GTP
cyclohydrolase 1 (CH1) in a single transcription unit has been
generated. In cultured striatal neurons transduced with this vector,
TH, AADC, and CH1 proteins can all be detected. After stereotactic
delivery into the dopamine-denervated striatum of the 6-OHDA-lesioned
rat, sustained expression of each enzyme and effective production of catecholamines were detected, resulting in significant reduction of
apomorphine-induced motor asymmetry compared with control animals (p < 0.003). Expression of each enzyme in
the striatum was observed for up to 5 months after injection. These
data indicate that the delivery of three catecholaminergic synthetic
enzymes by a single lentiviral vector can achieve functional
improvement and thus open the potential for the use of this vector for
gene therapy of late-stage PD patients.
Key words:
Parkinson's disease; dopamine replacement; lentiviral
vector; gene therapy; multicistronic vector; 6-OHDA; functional
recovery
*
M.A. and E.M.-R. contributed equally to this work.